Q: What is the STAR Trial?
Dr. Donnica: The STAR trial is an on-going study launched in June 1999,
by the National Surgical Adjuvant Breast and Bowel Project out of the National
Cancer Institute (NCI). The acronym stands for "Study of Tamoxifen and Raloxifene".
Both tamoxifen (Nolvadex) and raloxifene (Evista) are selective estrogen receptor
modulators (SERM's), which have a role in prevention of breast cancer in women
at high risk. The STAR trial aims to enroll 22,000 postmenopausal women who
are at increased risk for developing breast cancer. The goal of the study is
to determine whether raloxifene is also effective in reducing breast cancer
risk in high-risk women who have not had breast cancer, and whether this drug
has benefits over tamoxifen or fewer side effects. For more information on
this trial, click here.
Created: 11/16/2000  - Donnica Moore, M.D.